NASDAQ:VXRT Vaxart Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vaxart Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.75 -0.24 (-2.67 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$8.42Now: $8.75▼$9.2950-Day Range$4.78MA: $7.53▼$10.7552-Week Range$0.25Now: $8.75▼$17.49Volume17.74 million shsAverage Volume18.24 million shsMarket Capitalization$955.52 millionP/E RatioN/ADividend YieldN/ABeta-0.04 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.50, Vaxart has a forecasted upside of 122.9% from its current price of $8.75.Amount of Analyst CoverageVaxart has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesVaxart has received 284 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVaxart has received 281 “underperform” votes. (Add your “underperform” vote.)Community SentimentVaxart has received 50.27% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vaxart and other stocks. Vote “Outperform” if you believe VXRT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VXRT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $266,997,653.00 in company stock.Percentage Held by Insiders36.70% of the stock of Vaxart is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.90% of the stock of Vaxart is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vaxart are expected to grow in the coming year, from ($0.35) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -14.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -14.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 32.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CUSIPN/A CIK72444 Webwww.vaxart.com Phone650-550-3500Debt Debt-to-Equity Ratio0.03 Current Ratio3.98 Quick Ratio3.98Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.86 million Price / Sales96.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book32.41Profitability EPS (Most Recent Fiscal Year)($0.86) Net Income$-18,650,000.00 Net Margins-281.50% Return on Equity-84.90% Return on Assets-44.67%Miscellaneous Employees34 Outstanding Shares109,202,000Market Cap$955.52 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $8.75 -0.24 (-2.67 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VXRT News and Ratings via Email Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Vaxart (NASDAQ:VXRT) Frequently Asked Questions How has Vaxart's stock been impacted by Coronavirus? Vaxart's stock was trading at $2.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VXRT shares have increased by 322.7% and is now trading at $8.75. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Vaxart? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaxart. When is Vaxart's next earnings date? Vaxart is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Vaxart. How were Vaxart's earnings last quarter? Vaxart Inc (NASDAQ:VXRT) issued its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.06. The biotechnology company earned $0.52 million during the quarter, compared to analysts' expectations of $1.90 million. Vaxart had a negative net margin of 281.50% and a negative return on equity of 84.90%. View Vaxart's earnings history. When did Vaxart's stock split? How did Vaxart's stock split work? Vaxart's stock reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split. What price target have analysts set for VXRT? 2 analysts have issued 1-year target prices for Vaxart's stock. Their forecasts range from $17.00 to $22.00. On average, they expect Vaxart's share price to reach $19.50 in the next twelve months. This suggests a possible upside of 122.9% from the stock's current price. View analysts' price targets for Vaxart. Are investors shorting Vaxart? Vaxart saw a increase in short interest in August. As of August 14th, there was short interest totaling 13,840,000 shares, an increase of 110.3% from the July 30th total of 6,580,000 shares. Based on an average trading volume of 25,980,000 shares, the days-to-cover ratio is currently 0.5 days. View Vaxart's Short Interest. Who are some of Vaxart's key competitors? Some companies that are related to Vaxart include Ablynx (ABLYF), Denali Therapeutics (DNLI), bluebird bio (BLUE), Halozyme Therapeutics (HALO), Fate Therapeutics (FATE), Immunovant (IMVT), Twist Bioscience (TWST), Legend Biotech (PCVX), Sorrento Therapeutics (SRNE), Kodiak Sciences (KOD), Revolution Medicines (RVMD), Mesoblast (MESO), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT) and BAVARIAN NORDIC/S (BVNRY). View all competitors. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), Novavax (NVAX), ADMA Biologics (ADMA), OrganiGram (OGI) and Heat Biologics (HTBX). Who are Vaxart's key executives? Vaxart's management team includes the following people: Dr. Wouter W. Latour M.B.A., M.D., MBA, Pres, CEO, CFO & Director (Age 61)Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 51)Mr. John M. Harland M.B.A., CPA, Consultant (Age 67)Ms. Margaret A. Echerd, VP, Corp. Controller & Principal Accounting Officer (Age 60)Mr. Brant Biehn, Sr. VP of Commercial Operations What is Vaxart's stock symbol? Vaxart trades on the NASDAQ under the ticker symbol "VXRT." Who are Vaxart's major shareholders? Vaxart's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Goldman Sachs Group Inc. (0.37%), UBS Group AG (0.28%), Prudential Financial Inc. (0.27%), Jane Street Group LLC (0.19%), Hussman Strategic Advisors Inc. (0.18%) and Artal Group S.A. (0.18%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour. View institutional ownership trends for Vaxart. Which institutional investors are selling Vaxart stock? VXRT stock was sold by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., and Advisor Group Holdings Inc.. Company insiders that have sold Vaxart company stock in the last year include Armistice Capital, Llc, and Todd C Davis. View insider buying and selling activity for Vaxart. Which institutional investors are buying Vaxart stock? VXRT stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Prudential Financial Inc., UBS Group AG, Jane Street Group LLC, Artal Group S.A., Nuveen Asset Management LLC, Charles Schwab Investment Management Inc., and Balyasny Asset Management LLC. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour. View insider buying and selling activity for Vaxart. How do I buy shares of Vaxart? Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vaxart's stock price today? One share of VXRT stock can currently be purchased for approximately $8.75. How big of a company is Vaxart? Vaxart has a market capitalization of $955.52 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 34 workers across the globe. What is Vaxart's official website? The official website for Vaxart is www.vaxart.com. How can I contact Vaxart? Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
